Pramodini Medicare IPO GMP, Date, Price Band & Review

Pramodini Medicare IPO Details

Pramodini Medicare IPO is a 100% book-built issue of ₹69.04 crore, comprising a fresh issue of 0.54 crore shares worth up to ₹63.14 crore and an offer for sale (OFS) of 5.04 lakh shares worth up to ₹6 crore, with a face value of ₹10 per share. The company filed its DRHP with SEBI on April 23, 2026.

The price band of the issue is set between ₹110 and ₹118 per share and the lot size for an application is 1,200 shares. The minimum amount of investment required by an individual investor is ₹2,83,200 (2,400 shares). The IPO will open for subscription from August 12 to 14, 2026, on the NSE SME platform, with a tentative listing date fixed as August 19, 2026. The book-running lead manager of the issue is Smart Horizon Capital Advisors Private Limited, while the registrar to the offer is Purva Sharegistry (India) Private Limited.

Pramodini Medicare IPO Date & Timeline

The Pramodini Medicare IPO is officially set to open for subscription on Aug 12, 2026 and will close on Aug 14, 2026. The company initially filed its Draft Red Herring Prospectus (DRHP) on April 23, 2026 and has now finalized its schedule following SEBI approval. Once the subscription window closes, allotment is expected on Aug 17, 2026. Following this, the firm will initiate refunds and credit shares to successful investors' demat accounts on Aug 18, 2026. Finally, shares of Pramodini Medicare Ltd. are tentatively scheduled to list on the stock exchanges on Aug 19, 2026.

Company Background

Pramodini Medicare Ltd. was incorporated as a private limited company on 12 September, 2000, in Hyderabad, Andhra Pradesh. The company provides technology-enabled diagnostic services, which include radiology and clinical laboratory and nuclear medicine services, to public & private hospitals, with a presence in 14 cities in India.

Also, Pramodini Medicare provides teleradiology services and healthcare services. Overall, they operate as a one-stop solution for all services to the patients through their operational network and also provide customised health and wellness packages to meet the patients' requirements. On November 12, 2025, the company converted into a public limited company to proceed with its public listing procedures.

Operations & Product Range

The core operating model of Pramodini Medicare Ltd. revolves around delivering technology-driven diagnostic solutions. The company's services are broadly categorised into 3 segments: Radiology (accounting for the vast majority of revenue), Clinical Laboratory and Nuclear Medicine.

The product range includes advanced imaging modalities such as MRI, CT scans, PET-CT, X-rays and comprehensive pathology testing. The target customers are diverse, operating via B2G, B2B and B2C channels. By embedding diagnostic centres within existing public and private hospital infrastructures, the company efficiently accesses captive patient bases.

Facilities & Capacity

The operational infrastructure of Pramodini Medicare Ltd. is strong, with 16 diagnostic centres established across 7 states, spanning 14 cities in India. The company also operates a standalone centre in Vijayawada, which is equipped to conduct all laboratory collections and basic and advanced radiology tests. The company plans to deploy new medical equipment to expand capacity at its existing Hubli centre in Karnataka, commence operations with new equipment at Manjeri in Kerala, establish a proposed centre in Bangalore and upgrade existing machinery in Vijayawada.

Brands & Market Presence

Pramodini Medicare Ltd. has established a recognisable market presence under its flagship brand, functioning primarily within the domestic Indian market. The company has a concentrated geographic footprint, with its most dominant presence in Andhra Pradesh (contributing 61.90% of its operational revenue in FY26).

It has also successfully scaled its presence in Karnataka, contributing 20.82%, alongside operations in Uttar Pradesh (10.01%) and West Bengal (7.27%). By positioning its brand within established public and private healthcare institutions, the company leverages the credibility of its partners to reinforce its market position and ensure high visibility among target patient demographics.

Revenue Streams & Business Model

Pramodini Medicare Ltd. operates an asset-light diagnostic service business model centred on technology-enabled radiology, pathology and nuclear medicine. The company generates revenue across 4 primary operational channels: Public-Private Partnerships (PPP) with government hospitals, Private-Private Partnerships with private hospitals, strategic collaborations with Public Sector Undertakings (PSUs) and standalone private diagnostic centres. This multi-channel framework enables the firm to deliver healthcare diagnostic solutions across tier-I, tier-II and tier-III Indian cities.

Financial Performance

Pramodini Medicare Ltd. has shown a steady financial growth trajectory over the past 3 fiscal years. Total income increased from ₹38.55 crore in FY25 to ₹63.38 crore in FY26. The EBITDA also saw a consistent rise, moving from ₹20.97 crore in FY25 to ₹30.90 crore in FY26, with an EBITDA margin of 49.61% in FY26. Radiology is the company's principal service segment and drives the bulk of its top-line and bottom-line growth.

Management & Shareholding

The promoters of Pramodini Medicare Ltd. are Dr. Chalasani Kuldeep Kumar, Dr. Chalasani Kavitha, Ms. Chalasani Durga Aashritha, Ms. Chalasani Lalithakumari and M/s Sri Ram Medicare Private Limited. Before the IPO, the promoters held an 85.71% stake in the company, but after the IPO, the promoters’ shareholding will be diluted as the offering includes 5 lakh shares to be sold by existing shareholders and a fresh issue of 50.14 lakh shares to be issued for the general public.

Board & Key Management

The leadership of Pramodini Medicare Ltd. is led by a team of experts with many years of experience. Dr. Chalasani Kuldeep Kumar serves as the Chairman & Managing Director and gives strategic direction to the firm, as well as manages the daily operations, along with Whole-Time Directors. To ensure good governance, the board includes Independent Directors Mr. A Ajay Kumar, Dr. Eshwar Chandra Nandury and Mr. Manas Dash for honest oversight. Together, this team uses its knowledge to help the company grow and stay successful.